PIK3CA mutations are a predictor of docetaxel plus epirubicin neoadjuvant chemotherapy clinical efficacy in breast cancer
PIK3CA mutations are a predictor of docetaxel plus epirubicin neoadjuvant chemotherapy clinical efficacy in breast cancer
复制标题
PIK3CA突变是多西紫杉醇联合表阿霉素新辅助化疗乳腺癌临床疗效的预测因子
DOI：
10.4149/neo_2014_057
复制
发表时间：
2014-01-01
期刊：
影响因子：
3
通讯作者：
Li, X.
中科院分区：
文献类型：
--
作者：
Zhang, Y.;Liu, M.;Li, X.
本研究拟探讨PIK 3CA体细胞突变（人类乳腺癌（BC）中最常见的激活突变）与新辅助化疗（NCT）疗效的关系。应用新型液相芯片技术检测了93例接受表阿霉素联合多西他赛化疗的BC患者的PIK 3CA DNA体细胞突变和HER 2、PTEN、EGFR mRNA表达谱，其中30例PIK 3CA基因突变其中E542 K、E545 K、H1047 L和H1047 R点突变分别为4.3%、9.7%、4.3%和14.0%。PIK 3CA突变与患者的临床反应显著相关; 30例PIK 3CA突变患者中有27例具有部分或完全反应（p=0.002）。多变量分析进一步证实，在调整年龄、疾病分期和NCT周期后，PIK 3CA与临床应答相关（比值比0.126，95% CI [0.029，0.691]）。然而，在病理完全缓解（pCR，7/92）和非pCR组中PIK 3CA突变之间没有显著差异。此外，在93份样本中均未检测到EGFR、KRAS和BRAF突变。我们的数据首次表明，PIK 3CA突变状态可能是更好地了解BC患者对表阿霉素和多西他赛NCT联合治疗的临床应答的预测因子。
This study proposed to investigate the relationship of PIK3CA somatic mutations, the most common activating mutations in human breast cancer (BC), and the efficacy of neoadjuvant chemotherapy (NCT). Using a novel liquidchip technology, PIK3CA DNA somat ic mutations and HER2, PTEN, EGFR mRNA expression profiles were analyzed in formalin fixed paraffin embedded samples of 93 BC patients treated with epirubicin plus docetaxel NCT.PIK3CA mutations were found in 30 patients (32.3%), in which the point mutations of E542K, E545K, H1047L and H1047R were 4.3, 9.7, 4.3 and 14.0% respectively. The PIK3CA mutations were significantly associated with patients' clinical response; 27 of 30 PIK3CA mutated patients had either a partial or complete response (p=0.002). Multivariate analysis further confirmed that, after adjustments for age, disease stages and NCT cycles, PIK3CA was associated with clinical response (Odds Ration 0.126, 95% CI [0.029, 0.691]). However, there was no significant difference between PIK3CA mutations in pathological complete response (pCR, 7/92) and non-pCR group. Furthermore, no EGFR, KRAS and BRAF mutations were detected in any of the 93 samples. Our data for the first time suggested that PIK3CA mutation status may be a predictor for better understanding clinical response to the combination of epirubicin and docetaxel NCT in patients with BC.